New drug for Crohn's scarring passes early safety check in healthy volunteers

This early-stage study tested the safety of AGMB-129, a potential drug for fibrostenotic Crohn's disease, in 30 healthy adults. Participants received multiple doses of the drug or a placebo to see how well it was tolerated and how the body processes it. The goal was to find safe doses for future trials, not to treat any disease.